TL;DR: The Centers for Medicare & Medicaid Services modified NCD 61, its blood counts coverage policy, effective January 9, 2026. Here's what billing teams need to know before submitting claims.
CMS blood counts coverage policy under NCD 61 in the Medicare system covers complete blood counts (CBCs), hemograms, and differential white blood cell counts used to diagnose and monitor a wide range of hematological and secondary blood disorders. This modification clarifies the medical necessity criteria for blood count testing across red cell, white cell, and platelet disorders — and the breadth of covered indications is wider than many billing teams realize. The policy does not list specific CPT codes, so your team's documentation strategy becomes your primary claim defense.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Blood Counts |
| Policy Code | NCD 61 |
| Change Type | Modified |
| Effective Date | January 9, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology, Oncology, Internal Medicine, Primary Care, Nephrology, Gastroenterology, Cardiology, Obstetrics |
| Key Action | Audit documentation practices now to confirm every CBC order ties to a specific covered indication before January 9, 2026 |
CMS Blood Counts Coverage Criteria and Medical Necessity Requirements 2026
NCD 61 is the National Coverage Determination governing Medicare coverage of blood counts, including the complete blood count and hemogram. The Centers for Medicare & Medicaid Services updated this policy effective January 9, 2026. The modification reinforces that blood counts are covered when ordered for a documented clinical indication — and denials happen when that link is missing from the record.
The CBC is one of the most commonly ordered tests in Medicare billing. That's exactly why this coverage policy draws scrutiny. CMS knows that over-ordering is common, and this update sharpens the medical necessity standard without narrowing the list of covered indications.
What Medical Necessity Looks Like Under NCD 61
Medical necessity under this policy means the ordering provider can point to a specific sign, symptom, diagnosis, or clinical circumstance that justifies the test. That's not a high bar — but it has to be documented.
CMS organizes covered indications into three major categories: red cell disorders, white cell disorders, and platelet disorders. Each category has its own long list of qualifying signs and symptoms. The real issue for billing teams is that these lists are broad by design — CMS recognizes that hematological symptoms are often nonspecific and show up across dozens of conditions.
CBC and Hemogram: What Each Includes
The complete blood count includes the hemogram and a differential white blood cell count. The hemogram itself covers enumeration of red blood cells, white blood cells, and platelets, plus hemoglobin, hematocrit, and red cell indices. When a multichannel analyzer runs a sample, all of these parameters are measured together — that's why the CBC is routinely ordered rather than individual components.
This matters for blood counts billing because ordering a CBC and getting all components reimbursed is standard practice. What CMS is watching is whether the order itself is justified.
Prior Authorization Under NCD 61
This policy does not specify a prior authorization requirement for blood counts ordered in standard clinical settings. However, high-frequency ordering patterns — especially in outpatient labs — can trigger post-payment review. If your practice bills a high volume of CBCs, your compliance officer should review your ordering documentation before the effective date of January 9, 2026.
CMS Blood Counts Coverage Criteria and Medical Necessity: Condition-Level Detail 2026
This is where the policy gets useful. CMS spells out qualifying indications in granular detail. If your team is getting claim denials on CBC billing, the answer is almost always in this list — either the documentation doesn't reference a covered indication, or the indication wasn't recorded at the encounter level.
Red Cell Disorder Indications
CMS covers CBCs and hemograms ordered for signs and symptoms associated with anemia or other red blood cell disorders. The covered clinical triggers include: pallor, weakness, fatigue, weight loss, bleeding, acute injury with suspected blood loss, abnormal menstrual bleeding, hematuria, hematemesis, hematochezia, positive fecal occult blood test, malnutrition, vitamin deficiency, malabsorption, neuropathy, known malignancy, acute or chronic disease with associated anemia, coagulation or hemostatic disorders, postural dizziness, syncope, abdominal pain, change in bowel habits, chronic marrow hypoplasia, decreased red blood cell production, tachycardia, systolic heart murmur, congestive heart failure, dyspnea, angina, nailbed deformities, growth retardation, jaundice, hepatomegaly, splenomegaly, lymphadenopathy, and lower extremity ulcers.
That list is not a coincidence — it maps to the most common presenting complaints in primary care and internal medicine. CMS is telling you that the CBC is covered across a wide swath of clinical encounters. You just have to document why you ordered it.
CBCs for polycythemia also fall under red cell coverage. Qualifying signs include fever, chills, ruddy skin, conjunctival redness, cough, wheezing, cyanosis, clubbing of the fingers, orthopnea, heart murmur, headache, cognitive changes including memory changes, sleep apnea, weakness, pruritus, dizziness, excessive sweating, visual symptoms, weight loss, massive obesity, gastrointestinal bleeding, paresthesias, dyspnea, joint symptoms, and epigastric discomfort.
Bone Marrow and Systemic Indications
CMS explicitly covers CBC orders tied to evaluation of bone marrow dysfunction. This includes dysfunction caused by neoplasms, therapeutic agents, toxic substance exposure, and pregnancy. Also covered: suspected bone marrow failure or bone marrow infiltrate, suspected myeloproliferative processes, myelodysplastic processes, lymphoproliferative processes, immune disorders, and peripheral destruction of blood cells.
This category is important for oncology and hematology practices. If your team monitors patients on chemotherapy or immunosuppressive therapy, NCD 61 coverage supports serial CBC orders — as long as each order is tied to treatment monitoring documentation.
Coverage Indications at a Glance
| Indication Category | Covered? | Example Qualifying Signs/Symptoms | Notes |
|---|---|---|---|
| Anemia evaluation | Covered | Fatigue, pallor, weakness, tachycardia, dyspnea, positive FOBT, hematuria, hematemesis | Document specific symptom at encounter |
| Polycythemia evaluation | Covered | Ruddy skin, pruritus, headache, dizziness, conjunctival redness, visual symptoms | Link order to documented clinical finding |
| Bone marrow dysfunction — neoplasm | Covered | Known malignancy, suspected marrow failure or infiltrate | Specify neoplasm or suspected diagnosis |
| Bone marrow dysfunction — toxic/therapeutic agents | Covered | Chemotherapy, immunosuppressants, toxic substance exposure | Document agent and monitoring purpose |
| Bone marrow dysfunction — pregnancy | Covered | Pregnancy with suspected hematological complication | Routine prenatal CBC monitoring |
| Myeloproliferative / myelodysplastic / lymphoproliferative processes | Covered | Suspected or known process — evaluation and monitoring | Diagnosis or suspected diagnosis required |
| Immune disorders | Covered | Evaluation or monitoring of immune disorder affecting blood | Clinical documentation required |
| Platelet disorders (thrombocytosis, thrombocytopenia) | Covered | Bleeding, bruising, petechiae, coagulopathy | Specify platelet disorder or suspicion |
| White cell disorders (leukemia, leukocytosis, leukopenia) | Covered | Infection, fever, malignancy suspicion, lymphadenopathy | Clinical indication must be documented |
| Secondary hematological effects of non-blood diseases | Covered | Inflammation, infection, coagulopathy, neoplasm, toxic exposure | Underlying condition must be documented |
| Monitoring treatment effects | Covered | Chemotherapy, radiation, anticoagulation, other therapies | Treatment and monitoring rationale required |
| Inpatient hematological assessment | Covered | Possible hematological abnormality in inpatient setting | Multichannel analyzer panels covered |
| Routine CBC without documented clinical indication | Not Covered | No qualifying sign, symptom, diagnosis, or clinical circumstance | Lack of documentation = medical necessity failure |
CMS Blood Counts Billing Guidelines and Action Items 2026
The updated NCD 61 is not operationally complex — but it will generate claim denials if your documentation workflows don't match the medical necessity framework. Here's what to do before January 9, 2026.
| # | Action Item |
|---|---|
| 1 | Audit your CBC order documentation right now. Pull a sample of recent CBC claims and verify each one has a documented indication that maps to a covered category under NCD 61. This is your baseline. If you find gaps, you have a process problem to fix before the effective date. |
| 2 | Update your EHR order templates to require an indication field. Physicians ordering CBCs should not be able to submit a blank "routine" order without specifying why. The order should reference a sign, symptom, diagnosis code, or clinical circumstance that appears in the covered indications list. If your templates don't enforce this, fix them now. |
| 3 | Train ordering providers on the covered indications. The list is long — and that's actually good news. Almost every clinical encounter that warrants a CBC will have a qualifying indication. The problem is documentation, not clinical reality. A quick provider education session before January 9, 2026 will reduce your denial rate. |
| 4 | Review high-volume CBC billing patterns. If your lab or practice bills CBCs at high frequency, audit for patterns that could draw post-payment review. "Routine" or "wellness" orders without tied diagnoses are your exposure. Correct the documentation or add clinical justification retroactively where appropriate. |
| 5 | Confirm your ICD-10-CM codes align with the covered indications. NCD 61 does not list specific diagnosis codes, but your claim still needs a diagnosis code that supports the test order. Map your most common CBC-linked diagnoses to the covered indications in this policy. If a diagnosis code you're using doesn't fit a covered indication, your claim is at risk. |
| 6 | Talk to your compliance officer if you bill serial CBCs for monitoring. Monitoring coverage under NCD 61 is real — but it requires documentation that links each order to ongoing treatment effects. If your oncology or hematology team orders CBCs every cycle, make sure the documentation chain is intact. Your compliance officer should review this before January 9, 2026. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Blood Counts Under NCD 61
Covered CPT Codes
The policy data for NCD 61 does not list specific CPT or HCPCS codes. This is not unusual for a long-standing NCD — the coverage criteria apply to the service category (blood counts), and the CPT coding is handled at the claim level by your billing team.
The relevant CPT codes your team should be using for CBC and hemogram billing include the standard laboratory panel codes for complete blood counts with and without differential. Confirm these with your lab's charge master and current CPT code book. Do not rely on older code mappings — CPT updates the panel codes periodically, and your codes must match the current year's descriptor.
Key ICD-10-CM Guidance
NCD 61 does not enumerate specific ICD-10-CM codes. Your diagnosis codes must reflect the clinical indication documented by the ordering provider. Examples of diagnosis code categories that align with covered indications include:
- Anemia and anemia-related conditions
- Polycythemia vera and secondary polycythemia
- Leukemia and lymphoma (including suspected/rule-out)
- Thrombocytopenia and thrombocytosis
- Myeloproliferative and myelodysplastic disorders
- Coagulation defects
- Malnutrition and vitamin deficiency states
- Neoplasms requiring treatment monitoring
- Conditions with documented secondary hematological effects
Work with your coding team to build a crosswalk between your most common ordering diagnoses and the NCD 61 covered indications. This crosswalk is your first line of defense against claim denial.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.